# A Moderate to Severe Rheumatoid Arthritis Study

> **NCT01721044** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 527 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Placebo
- **DRUG:** Baricitinib
- **DRUG:** cDMARD

## Key facts

- **NCT ID:** NCT01721044
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2014-06
- **Final completion:** 2014-09
- **Target enrollment:** 527 (ACTUAL)
- **Last updated:** 2019-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01721044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01721044, "A Moderate to Severe Rheumatoid Arthritis Study". Retrieved via AI Analytics 2026-09-24 from https://api.ai-analytics.org/clinical/NCT01721044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*